{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:03:59Z","timestamp":1793822639373,"version":"4.6.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ekir.2026.103796","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:23:19Z","timestamp":1769271799000},"page":"103796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucocorticoid reduction in Glomerular Diseases"],"prefix":"10.1016","volume":"11","author":[{"given":"Michael","family":"Toal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Canney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Fairhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Massicotte-Azarniouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.103796_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2026.103796_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener\u2019s granulomatosis","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"issue":"Suppl","key":"10.1016\/j.ekir.2026.103796_bib3","first-page":"29","article-title":"European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in systemic vasculitis ECSYSVASTRIAL","volume":"101","author":"Rasmussen","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2026.103796_bib4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.kint.2024.11.029","article-title":"The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial","volume":"107","author":"Odler","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103796_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib7","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103796_bib8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of Reduced-Dose vs High-Dose glucocorticoids Added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.103796_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050507","article-title":"Original research: comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review","volume":"12","author":"Xiao","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ekir.2026.103796_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/PNXB5040","article-title":"Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT","volume":"26","author":"Jayne","year":"2022","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ekir.2026.103796_bib12","article-title":"The use of glucocorticoids in lupus nephritis: new pathways for an old drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.103796_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.ekir.2026.103796_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib15","doi-asserted-by":"crossref","first-page":"E1286","DOI":"10.34067\/KID.0000000000000222","article-title":"Low-dose intravenous methylprednisolone in remission induction therapy for ANCA-associated vasculitis","volume":"4","author":"Floyd","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.103796_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard-2024-226339","article-title":"Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"84","author":"Nagle","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib17","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ekir.2025.07.022","article-title":"Glucocorticoid dosing and outcomes in ANCA-associated vasculitis with kidney involvement","volume":"10","author":"Salman","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103796_bib18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103796_bib19","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2026.103796_bib20","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ekir.2025.04.030","article-title":"Combination cyclophosphamide and rituximab to minimize glucocorticoid use in antineutrophil cytoplasm antibody\u2013associated vasculitis","volume":"10","author":"Salehi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103796_bib21","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ekir.2025.03.009","article-title":"Long-term follow-up of a glucocorticoid minimizing regimen for the treatment of severe antineutrophil cytoplasmic autoantibody\u2013associated vasculitis","volume":"10","author":"McAdoo","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103796_bib22","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41927-025-00456-4","article-title":"Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan","volume":"9","author":"Tagami","year":"2025","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.ekir.2026.103796_bib25","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2026.103796_bib26","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/keae359","article-title":"Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study","volume":"64","author":"Gabilan","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2026.103796_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103796_bib29","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.103796_bib30","doi-asserted-by":"crossref","first-page":"i88","DOI":"10.1093\/rheumatology\/keae490","article-title":"Highlights from the plenary session: advances in treatment (I)","volume":"64","author":"Smith","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2026.103796_bib31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103796_bib32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib33","first-page":"CD002922","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","volume":"6","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2026.103796_bib34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the control arms of randomized controlled trials","volume":"76","author":"Figueroa-Parra","year":"2024","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.ekir.2026.103796_bib35","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2026.103796_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/1756-185X.14265","article-title":"Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients","volume":"25","author":"Bandhan","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/ijn.IJN_299_18","article-title":"Comparison of two steroid regimens in induction therapy of proliferative lupus nephritis: a randomized controlled trial","volume":"29","author":"Bharati","year":"2019","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib38","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 Aurora 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.ekir.2026.103796_bib40","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40697-014-0030-9","article-title":"The Steroids in the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial","volume":"1","author":"Galbraith","year":"2014","journal-title":"Can J Kidney Heal Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000495352","article-title":"Short-term steroid regimen for adult steroid-sensitive minimal change disease","volume":"49","author":"Ozeki","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib45","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2026.103796_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ndt\/gfp422","article-title":"Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome","volume":"25","author":"Eguchi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.103796_bib47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1440-1797.2006.00667.x","article-title":"Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation","volume":"11","author":"Miao","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2026.103796_bib48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.2019050546","article-title":"Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults","volume":"32","author":"Chin","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib49","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib51","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.kint.2018.07.021","article-title":"An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study)","volume":"94","author":"R\u00e9my","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103796_bib52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/qjmed\/hcz297","article-title":"Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease","volume":"113","author":"Ma","year":"2020","journal-title":"QJM"},{"key":"10.1016\/j.ekir.2026.103796_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1681\/ASN.0000000520","article-title":"Long-term outcomes of rituximab-treated adult patients with podocytopathies","volume":"36","author":"Gauckler","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib54","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","article-title":"Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance","volume":"29","author":"Guitard","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.103796_bib55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103796_bib56","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103796_bib57","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1001\/jama.2025.19316","article-title":"Rituximab for relapsing nephrotic syndrome in adults: a randomized clinical trial","volume":"334","author":"Isaka","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.103796_bib58","article-title":"Interventions for focal segmental glomerulosclerosis in adults","volume":"2","author":"Hodson","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2026.103796_bib59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study","volume":"23","author":"Senthil Nayagam","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.103796_bib60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib61","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.103796_bib62","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.103796_bib63","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/0886022X.2021.1963775","article-title":"Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial","volume":"43","author":"Ni","year":"2021","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2026.103796_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41598-021-03691-0","article-title":"Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.103796_bib65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib67","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.103796_bib68","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group","volume":"327","author":"Ponticelli","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.103796_bib70","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103796_bib71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ndt\/gfae138","article-title":"A novel approach to induce early remission in high-risk primary membranous nephropathy","volume":"40","author":"Kochoyan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.103796_bib72","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:25:07Z","timestamp":1775265907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2468024926000276"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.103796","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoid reduction in Glomerular Diseases","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.103796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103796"}}